TPO-RA Plus Baricitinib vs. TPO-RA for ITP

This is a prospective, randomized, controlled trial. ITP patients who failed prior full-does TPO-RA monotheray for 14 days. Patients are randomly assigned at a 1:1 ratio to receive baricitinib plus TPO-RA or TPO-RA alone. Patients are randomly assigned at a 1:1 ratio to receive baricitinib plus TPO-RA or TPO-RA alone. The primary endpoint was the 14-day overall response rate without any rescue therapy.

NCT Number	NCT07669675
Lead Sponsor	Peking University People's Hospital
Conditions	ITP - Immune Thrombocytopenia
Enrollment	100 participants
Start Date	2026-07-01
Primary Completion	2027-12-31 (estimated)
Study Completion	2028-08-31 (estimated)
Updated on ClinicalTrials.gov	2026-06-25